OBJECTIVE: To compare the clinical characteristics and outcomes of HIV-1-HTLV-1 coinfected patients, in Bahia, Brazil. METHODS: Retrospective, comparative study. RESULTS: Among a total of 123 consecutive HIV infected patients, 20 men (20.6%) and 6 women (23.1%) had detectable antibodies against HTLV-I/II. The major risk factor associated with coinfection by HTLV was intravenous drug use (57.7% of coinfected patient versus 9.2% of HTLV seronegative patients, p < 0.0001). Coinfected patients had higher absolute lymphocyte counts (1,921 + 762 versus 1,587 + 951, p = 0.03). Both groups of patients had similar means of CD4+ and CD8+ cell counts. However, among patients with AIDS CD4+ cell counts were significantly higher among those coinfected with HTLV-I/II (292 ± 92 cells/mm³, versus 140 ± 177 cells/mm³, p = 0.36). The frequency and type of opportunistic infections were similar for both groups, but strongyloidiasis and encephalopathy were more frequently diagnosed in coinfected patients (p < 0.05). On the other hand, patients coinfected with HTLV-I/II received significantly less antiretroviral therapy than singly infected by HIV-1. CONCLUSION: Coinfection by HTLV-I/II is associated with an increased risk of strongyloidiasis for HIV patients. Higher CD4 count may lead to underestimation of immunodeficiency, and delay to initiate antiretroviral therapy.
OBJECTIVE: To compare the clinical characteristics and outcomes of HIV-1-HTLV-1 coinfectedpatients, in Bahia, Brazil. METHODS: Retrospective, comparative study. RESULTS: Among a total of 123 consecutive HIV infectedpatients, 20 men (20.6%) and 6 women (23.1%) had detectable antibodies against HTLV-I/II. The major risk factor associated with coinfection by HTLV was intravenous drug use (57.7% of coinfectedpatient versus 9.2% of HTLV seronegative patients, p < 0.0001). Coinfectedpatients had higher absolute lymphocyte counts (1,921 + 762 versus 1,587 + 951, p = 0.03). Both groups of patients had similar means of CD4+ and CD8+ cell counts. However, among patients with AIDSCD4+ cell counts were significantly higher among those coinfected with HTLV-I/II (292 ± 92 cells/mm³, versus 140 ± 177 cells/mm³, p = 0.36). The frequency and type of opportunistic infections were similar for both groups, but strongyloidiasis and encephalopathy were more frequently diagnosed in coinfectedpatients (p < 0.05). On the other hand, patientscoinfected with HTLV-I/II received significantly less antiretroviral therapy than singly infected by HIV-1. CONCLUSION: Coinfection by HTLV-I/II is associated with an increased risk of strongyloidiasis for HIVpatients. Higher CD4 count may lead to underestimation of immunodeficiency, and delay to initiate antiretroviral therapy.
Authors: Mariana Cavalheiro Magri; Luis Fernando de Macedo Brigido; Rosangela Rodrigues; Helena Kaminami Morimoto; Adele Caterino-de-Araujo Journal: AIDS Res Hum Retroviruses Date: 2012-04-20 Impact factor: 2.205
Authors: Fabiana Martins de Paula; Fernanda Mello Malta; Marcelo Andreetta Corral; Priscilla Duarte Marques; Maiara Gottardi; Dirce Mary Correia Lima Meisel; Juliana Yamashiro; João Renato Rebello Pinho; Vera Lucia Pagliusi Castilho; Elenice Messias do Nascimento Gonçalves; Ronaldo César Borges Gryschek; Pedro Paulo Chieffi Journal: Rev Inst Med Trop Sao Paulo Date: 2016-09-22 Impact factor: 1.846
Authors: Rosa Maria N Marcusso; Johan Van Weyenbergh; João Victor Luisi de Moura; Flávia Esper Dahy; Aline de Moura Brasil Matos; Michel E J Haziot; Jose E Vidal; Luiz Augusto M Fonseca; Jerusa Smid; Tatiane Assone; Jorge Casseb; Augusto César Penalva de Oliveira Journal: Pathogens Date: 2019-12-26